Ketamine infusion therapy in treatment-resistant depression
Psychiatriki December 20, 2021 DOI: 10.22365/jpsych.2021.051 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractThe FDA has approved S-ketamine nasal spray for treatment-resistant depression, marking a new class of psychiatric drugs. This approval comes 30 years after psychedelics were first studied for mental health treatment. Intravenous ketamine infusion has been researched for depression since the 1990s. The article describes the current protocol for ketamine infusion therapy in patients with treatment-resistant depression and provides related clinical information.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Intervention | Intravenous ketamine infusion |
| Topics | Depression Ketamine |
| Keywords | Depression economics Medicine Electroconvulsive therapy |
| Citations | 1 |
| Key finding | The FDA approval of S-ketamine nasal spray represents a new category of therapeutic agents in psychiatry, and intravenous ketamine infusion has been studied for depression since the 1990s. |
Abstract
Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry. A well-known class of substances, psychedelics, are introduced with a 30-year delay in the treatment of mental disorders. Intravenous ketamine infusion has been studied in the treatment of depression since the 1990s. Here we present the current protocol for the treatment of ketamine infusion in patients with treatment-resistant depression and related clinical information.